1. Home
  2. Biosimilar
  Subject:

Biosimilar   New Search

View on DBpedia    View on Wikipedia
Top related subjects:
 Infliximab Rheumatoid arthritis Filgrastim Pharmacokinetics Monoclonal antibody Inflammatory bowel disease Hormone Ulcerative colitis PubMed Performance status Biosimilar Adalimumab Antibody Osteoarthritis Methotrexate Systemic lupus erythematosus Arthritis Protein Pegfilgrastim Hematopoietic stem cell Granulocyte colony-stimulating factor Chemotherapy Blood plasma Bioavailability Enzyme inhibitor Biological half-life Pharmacodynamics Growth factor Antigen Microbiota Colitis Gastrointestinal tract Estrogen receptor Breast cancer Gene Metabolism Colorectal cancer Embase Cochrane Library MEDLINE Scopus Clinical trial Radiation therapy Multivariate analysis Progression-free survival Eastern Cooperative Oncology Group
RELATED SUBJECTS:
The publications listed also have these subjects
Infliximab  5 times
Rheumatoid arthritis  4 times
Pharmacokinetics  3 times
Monoclonal antibody  3 times
Inflammatory bowel disease  3 times
Hormone  3 times
Ulcerative colitis  2 times
PubMed  2 times
Performance status  2 times
Neutropenia  2 times
International law  2 times
Granulocyte colony-stimulating factor  2 times
European Medicines Agency  2 times
Chemotherapy  2 times
Antibody  2 times
Anemia  2 times
Adalimumab  2 times
Tumor necrosis factor alpha  1 time
Transfection  1 time
Single Center  1 time
Rituximab  1 time
Rheumatology  1 time
Protein  1 time
Precision medicine  1 time
Polyethylenimine  1 time
Polyethylene  1 time
Plasmid  1 time
Pharmacovigilance  1 time
Pharmacodynamics  1 time
Ovulation  1 time
Myalgia  1 time
Metabolism  1 time
Memory  1 time
Lymphoma  1 time
Juvenile idiopathic arthritis  1 time
Italy  1 time
International  1 time
Industrial fermentation  1 time
Immunoassay  1 time
Hypoesthesia  1 time
Hematopoietic stem cell  1 time
Growth hormone  1 time
Growth factor  1 time
Gold standard  1 time
Glycan  1 time
Gene  1 time
Etanercept  1 time
Erythropoietin  1 time
Embase  1 time
Electrochemiluminescence  1 time
Eastern Cooperative Oncology Group  1 time
Dialysis  1 time
DNA  1 time
ClinicalTrials.gov  1 time
Clinical trial  1 time
Chronic kidney disease  1 time
Cervical cancer  1 time
Canada  1 time
CD34  1 time
Breast cancer  1 time
Bone density  1 time
Blood transfusion  1 time
Blood lipids  1 time
Biotechnology  1 time
Biomimetics  1 time
Bevacizumab  1 time
Bcl-xL  1 time
B-cell chronic lymphocytic leukemia  1 time
Assisted reproductive technology  1 time
Arthralgia  1 time
Apoptosis  1 time
Apheresis  1 time
Ankylosing spondylitis  1 time
Angiogenesis  1 time
Adverse drug reaction  1 time
Adjuvant  1 time

Publications tagged with this subject: 23

Note: Top 50 publications shown only. Open an item panel to view more info (open all)


1. Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis

2. Clinical Trial Design in Juvenile Idiopathic Arthritis

3. Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors

4. CT-P10 (Truxima™): A Rituximab Biosimilar

5. Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab

6. Long-term safety and efficacy of Omnitrope® in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults study

7. A BioDesign Approach to Obtain High Yields of Biosimilars by Anti-apoptotic Cell Engineering: a Case Study to Increase the Production Yield of Anti-TNF Alpha Producing Recombinant CHO Cells

8. Update on Biosimilars in Asia

9. Manufacturing of Recombinant Human Follicle-Stimulating Hormone Ovaleap® (XM17), Comparability with Gonal-f®, and Performance/Consistency

10. Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months

11. Physicochemical Properties, Toxicity, and Specific Activity of a Follitropin Alpha Biosimilar

12. Long-Term Clinical Outcomes After Switching from Remicade® to Biosimilar CT-P13 in Inflammatory Bowel Disease

13. Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?

14. A retrospective open-label uncontrolled study of Epoetin zeta on the treatment of chemotherapy-induced anemia in solid tumors

15. Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents

16. Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study

17. Patient and Healthcare Professionals Preference for Brenzys vs. Enbrel Autoinjector for Rheumatoid Arthritis: A Randomized Crossover Simulated-Use Study

18. Comparative efficacy and safety in ESA biosimilars vs. originators in adults with chronic kidney disease: a systematic review and meta-analysis

19. Interchangeability of Biosimilars: A European Perspective

20. Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community

21. Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease

22. Impact of Guidance on the Prescription Patterns of G-CSFs for the Prevention of Febrile Neutropenia Following Anticancer Chemotherapy: A Population-Based Utilization Study in the Lazio Region

23. Clinical equivalence with G-CSF biosimilars: methodologic approach in a (neo)adjuvant setting in non-metastatic breast cancer


Questions?

Drop us a message.